Now showing items 1-3 of 3

    • Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients 

      Nunes, Fabio; Merker, Vanessa L.; Jennings, Dominique; Caruso, Paul Albert; di Tomaso, Emmanuelle; Muzikansky, Alona; Barker, Frederick George; Stemmer-Rachamimov, Anat; Plotkin, Scott Randall (Public Library of Science (PLoS), 2013)
      Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some neurofibromatosis 2 (NF2) patients but its effect on meningiomas has not been defined. To determine the clinical activity ...
    • Current status and recommendations for biomarkers and biobanking in neurofibromatosis 

      Hanemann, C. Oliver; Blakeley, Jaishri O.; Nunes, Fabio; Robertson, Kent; Stemmer-Rachamimov, Anat; Mautner, Victor; Kurtz, Andreas; Ferguson, Michael Andrew; Widemann, Brigitte C.; Evans, D. Gareth; Ferner, Rosalie; Carroll, Steven L.; Korf, Bruce; Wolkenstein, Pierre; Knight, Pamela; Plotkin, Scott Randall (Ovid Technologies (Wolters Kluwer Health), 2016)
      Objective: Clinically validated biomarkers for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis (SWN) have not been identified to date. The biomarker working group’s goals are to (1) define ...
    • Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas 

      Engler, David A; Roy, Jennifer; Shen, Yiping; Nunes, Fabio Pereira; Stemmer-Rachamimov, Anat; James, Marianne F.; Mohapatra, Gayatry; Plotkin, Scott Randall; Betensky, Rebecca Aubrey; Ramesh, Vijaya; Gusella, James Francis (BioMed Central, 2009)
      Background: Meningiomas may occur either as familial tumors in two distinct disorders, familial multiple meningioma and neurofibromatosis 2 (NF2), or sporadically, as either single or multiple tumors in individuals with ...